959778-16-6

Upstream product

• 128566-93-8 2-bromo-4-nitrobenzoic acid ethyl ester 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 64-17-5 ethanol 
• 100959-22-6 methyl 2-bromo-4-nitrobenzoate 
• 16426-64-5 2-bromo-4-nitrobenzoic acid 

Downstream Products

• 1211589-24-0 methyl 4-amino-2-ethyl-benzoate 
• 1283128-54-0 ethyl 4-amino-2-ethyl-benzoate 

Relevant academic research and scientific papers

NOVEL IMIDAZOPYRAZINE DERIVATIVES

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Impact of electronic modification of the chelating benzylidene ligand in cis-dichloro-configured second-generation olefin metathesis catalysts on their activity

A series of electronically modified second-generation cis-dichloro ruthenium ester chelating benzylidene complexes was prepared, characterized, and benchmarked in a typical ring-opening metathesis polymerization (ROMP) experiment. The electronic tuning of the parent chelating benzylidene ligand (2-ethyl ester benzylidene) was achieved by substitution at the 4- and 5-positions with electron-withdrawing nitro or electron-donating methoxy groups. The effect of the electronic tuning on the cis-trans isomerization process was studied experimentally and theoretically. Density functional theory calculations clearly revealed the influence of electronic modification on the relative stability between the cis and trans isomers, which is decisive for the activity of the studied compounds as initiators in ROMP.

PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION

The present invention relates to certain phenyl-urea and phenyl-carbamate derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, and multiple system atrophy.

2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The present invention relates to novel oxadiazole derivatives of formula (1) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic α7 receptor formula (I).